Effect of antiandrogen, chlormadinone acetate (CMA), in canine spontaneous benign prostatic hyperplasia (BPH).
The effect of synthetic steroidal antiandrogen, chlormadinone acetate (CMA), on spontaneous benign prostatic hyperplasia (BPH) in dogs was investigated. Male beagle dogs (5-8 years old) were divided into three experimental groups. Group 1 consisted of untreated controls. Groups 2 and 3 received CMA 0.03, and 0.1 mg/kg/day, p.o., respectively, for 6 months. In group 1, glandular hyperplasia of the prostate was clearly detected. In groups 2 and 3, CMA produced marked atrophy of the glandular epithelium. In addition, a histopathological study showed that CMA medication for 6 months exerted no effect on the testes and adrenals or on immunoreactive LH- and ACTH- cells of the anterior pituitary glands. Therefore, it is suggested that CMA (0.03 and 0.1 mg/kg) causes regression of spontaneous canine BPH without any histopathological effects on the testes, adrenals or anterior pituitary LH- and ACTH-cells.
Murakoshi
M
M
Safety Research Department, Teikoku Hormone Mfg. Co., Ltd., Kawasaki, Japan.
Ikada
R
R
Tagawa
M
M
Nakayama
T
T
D000311:Adrenal Glands / Q000737:chemistry / Q000187:drug effects / Q000473:pathology; D000324:Adrenocorticotropic Hormone / Q000032:analysis; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D002715:Chlormadinone Acetate / Q000008:administration & dosage / Q000494:pharmacology*; D004285:Dogs; D007986:Luteinizing Hormone / Q000032:analysis; D008297:Male; D009929:Organ Size; D010903:Pituitary Gland, Anterior / Q000187:drug effects / Q000473:pathology; D011467:Prostate / Q000187:drug effects / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology; D013737:Testis / Q000187:drug effects / Q000473:pathology
D000726:Androgen Antagonists; D002715:Chlormadinone Acetate; D000324:Adrenocorticotropic Hormone; D007986:Luteinizing Hormone